Hope Or Hype: The Obsession with Medical Advances and the High Cost of False Promises
AMACOM Div American Mgmt Assn, 2005 - Business & Economics - 335 pages
Annotation Medical science has always promised -- and often delivered -- a longer, better life. But as the pace of science accelerates, do our expectations become unreasonable, fueled by an industry bent on profits and a media desperate for big news?Hope or Hype is a taboo-shattering look at what drives the American obsession with medical "miracles," exposing the equipment manufacturers and pharmaceutical companies; doctors and hospitals too quick to order surgery; the politicians; the press; and our own "technoconsumption" mindset. The authors spread blame for the parade of so-called miracle cures that too often are marginally effective at best -- and sometimes downright dangerous. They examine consumers? eager embrace of medical advances, and present riveting stories of the conscientious doctors and researchers who blew the whistle on ineffective treatments. Finally, they provide sane, practical recommendations for the adoption of new developments. The consequences of questionable practices include costly recalls, billions in wasted money, and the pain and suffering of innumerable patients and their families. In short, they must stop.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Medical Innovations and American Culture
Why More Isnt Always Better
Why Newer Isnt Always Better
What Will You Swallow?
Making Friends Playing Monopoly and Dirty Tricks
Stacking the Deck?
Ineffective or Needlessly Extensive Surgery
Weight Loss Technology
Opinion Makers and Regulators
For Insurers and Researchers
For All Decision Makers
2O For Government
Other editions - View all
advertising advocacy groups agency alteplase American approval argue artery arthritis artificial heart back pain benefit better bone marrow transplant breast cancer calcium-channel blockers catheter Center chemotherapy Claritin clinical trials complications conflicts of interest consumers costs decisions direct-to-consumer disease diuretics doctors drug companies drug industry drug makers drugs and devices encainide episiotomy evaluation evidence-based evidence-based medicine example expensive experts flecainide funding guidelines health-care heart attacks high blood pressure hospital increase JAMA less lung major manufacturers medical advances medical devices medical journals Medicare medicine ments million NEngl Neurontin operation patients percent Pfizer pharmaceutical physicians placebo prescribing problems procedures promote prostate cancer Psaty Psaty's randomized trials recent reported risk Schering-Plough scientific side effects sometimes spinal fusion stories stroke surgeons surgery surgical Synthroid Taxol tests therapy there's tion treat treatment Wall Street Journal women York